Program
Olanzapine
Also written as “olanzapine”, “ALKS 3831” and “Olanzapine Tablets 5 mg”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Treatment-Resistant · Fasting · Borderline Personality Disorder, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 360 open or running | phase 4since Apr 30, 2002 | Apr 30, 2002 | none ahead |
| Viatris | 50 open or running | phase 4since Oct 12, 2005 | Sep 1, 2005 | none ahead |
| Dr. Reddy's Laboratories | 40 open or running | phase 1since Jan 2, 2012 | Jan 2, 2012 | none ahead |
| Abbott | 20 open or running | phase 4since Oct 16, 2003 | Oct 16, 2003 | none ahead |
| AstraZeneca | 10 open or running | phase 3since May 2, 2002 | May 2, 2002 | none ahead |
| HK inno.N | 10 open or running | phase 4since May 11, 2014 | May 11, 2014 | none ahead |
| joint-stock-company-farmak | 10 open or running | phase 1since Nov 15, 2021 | Nov 15, 2021 | none ahead |
| neurelis-inc | 10 open or running | phase 1since Sep 6, 2024 | Sep 6, 2024 | none ahead |
| orexigen-therapeutics-inc | 10 open or running | phase 2since Aug 12, 2008 | Aug 12, 2008 | none ahead |
| Qilu Pharmaceutical | 10 open or running | phase 3since Mar 27, 2023 | Mar 27, 2023 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 1since Mar 13, 2024 | Mar 13, 2024 | none ahead |
Also a collaborator on its studies: Pfizer and H. Lundbeck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 35 studies since Apr 30, 2002.
- Feb 8, 2008Phase 3 study in Bipolar I DisorderEli Lilly · NCT00618748 · 101 enrolled · Japan
- Mar 18, 2008Phase 3 study in SchizophreniaEli Lilly · NCT00640510 · 34 enrolled · Japan
- Mar 30, 20083 phase 1 studies in HealthyViatris · NCT00648921, NCT00647972, NCT00647777
- Aug 12, 2008orexigen-therapeutics-inc's first study: phase 2 study in SchizophreniaNew to orexigen-therapeutics-incorexigen-therapeutics-inc · NCT00734435 · 26 enrolled · United States
- Oct 3, 2008Phase 4 study in Bipolar DisorderEli Lilly · NCT00767715 · 11 enrolled · Sweden
- Aug 12, 2009Phase 3 study in Depressive Disorder, Treatment-ResistantEli Lilly · NCT00958568 · 892 enrolled · United States, Argentina, India and more
- Sep 1, 2009Phase 3 study in SchizophreniaEli Lilly · NCT00970281 · 91 enrolled · Japan
- Jan 2, 2012Dr. Reddy's Laboratories's first studies: 4 phase 1 studiesNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01503450, NCT01503437, NCT01503424 and 1 more
- Sep 7, 2012Phase 3 study in Depressive Disorder, Treatment-ResistantEli Lilly · NCT01687478 · 176 enrolled · China
- May 11, 2014HK inno.N's first study: phase 4 study in SchizophreniaNew to HK inno.NHK inno.N · NCT02137993 · 64 enrolled
- Nov 15, 2021joint-stock-company-farmak's first study: phase 1 study in PharmacokineticsNew to joint-stock-company-farmakjoint-stock-company-farmak · NCT05123976 · 32 enrolled · Czechia
- Mar 27, 2023Qilu Pharmaceutical's first study: phase 3 study in Acute AgitationNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT05803642 · 318 enrolled
- Mar 13, 2024Teva Pharmaceutical Industries's first study: phase 1 study in SchizophreniaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT06319170 · 106 enrolled · United States
- Sep 6, 2024neurelis-inc's first study: phase 1 study in HealthyNew to neurelis-incneurelis-inc · NCT06600477 · 24 enrolled · Jordan
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule
Studies
All 54 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06600477Healthy · Jordan | 1 | Completed | neurelis-inc | Nov 1, 2023 | 24 |
| NCT06319170Schizophrenia · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 15, 2025 | 106 |
| NCT05803642Acute Agitation | 3 | UNKNOWN | Qilu Pharmaceutical | May 7, 2024 | 318 |
| NCT05123976Pharmacokinetics · Czechia | 1 | Completed | joint-stock-company-farmak | Nov 30, 2020 | 32 |
| NCT02137993Schizophrenia | 4 | Completed | HK inno.N | May 2013 | 64 |
| NCT01687478Depressive Disorder, Treatment-Resistant · China | 3 | Terminated | Eli Lilly | Nov 2015 | 176 |
| NCT01503450Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | Dr. Reddy's Laboratories | Dec 2006 | 26 |
| NCT01503437Fasting · India | 1 | Completed | Dr. Reddy's Laboratories | Nov 2006 | 22 |
| NCT01503424Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2011 | 48 |
| NCT01503398Fasting · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2011 | 48 |
| NCT00970281Schizophrenia · Japan | 3 | Completed | Eli Lilly | Apr 2011 | 91 |
| NCT00958568Depressive Disorder, Treatment-Resistant · United States, Argentina, India and more | 3 | Completed | Eli Lilly | Mar 2012 | 892 |
| NCT00767715Bipolar Disorder · Sweden | 4 | Terminated | Eli Lilly | Apr 2005 | 11 |
| NCT00734435Schizophrenia · United States | 2 | Terminated | orexigen-therapeutics-inc | Dec 2008 | 26 |
| NCT00648921Healthy · United States | 1 | Completed | Viatris | Jul 2003 | 30 |
| NCT00647972Healthy · United States | 1 | Terminated | Viatris | May 2003 | 32 |
| NCT00647777Healthy · United States | 1 | Completed | Viatris | Jul 2003 | 32 |
| NCT00640510Schizophrenia · Japan | 3 | Completed | Eli Lilly | Jul 2008 | 34 |
| NCT00618748Bipolar I Disorder · Japan | 3 | Completed | Eli Lilly | Sep 2010 | 101 |
| NCT00510146Bipolar Disorder · China, Japan, Korea, Republic of | 3 | Completed | Eli Lilly | Mar 2010 | 514 |
| NCT00485771Bipolar Disorder · United States | 4 | Completed | Eli Lilly | 403 | |
| NCT00402324Bipolar I Disorder · United States | 4 | Completed | Eli Lilly | Feb 2008 | 202 |
| NCT00401973Schizophrenia · United States, Brazil, Israel and more | 3 | Completed | Eli Lilly | Sep 2008 | 199 |
| NCT00347425Schizophrenia · United States, Argentina, Canada and more | 3 | Completed | Abbott | Feb 2008 | 286 |
| NCT00337662Schizophrenia · United States, Argentina, Russian Federation | 4 | Completed | Eli Lilly | Dec 2007 | 628 |
| NCT00303602Schizophrenia · United States, Canada, Mexico and more | 4 | Completed | Eli Lilly | Dec 2007 | 149 |
| NCT00266630Mania · Japan | 3 | Completed | Eli Lilly | May 2009 | 139 |
| NCT00259272Bipolar Disorder I or II · France | 3 | Completed | Eli Lilly | May 2008 | 141 |
| NCT00239109Schizophrenia · Spain | 4 | Completed | Viatris | 112 | |
| NCT00191997Bipolar Disorder · Spain | 4 | Completed | Eli Lilly | 180 | |
| NCT00191828Weight Gain · Italy | 4 | Completed | Eli Lilly | 60 | |
| NCT00191555Schizophrenia · France | 4 | Completed | Eli Lilly | 360 | |
| NCT00190892Bipolar Disorder · Australia, Greece, Hungary and more | 4 | Completed | Eli Lilly | 120 | |
| NCT00190749Schizophrenia · United States | 4 | Completed | Eli Lilly | Jun 2008 | 130 |
| NCT00145444Schizophrenia · Belgium, Netherlands | 3 | Completed | Viatris | 100 | |
| NCT00129220Bipolar Disorder · Japan | 3 | Completed | Eli Lilly | Jan 2009 | 224 |
| NCT00113594Schizophrenia · United States, Puerto Rico, Russian Federation | 3 | Completed | Eli Lilly | 100 | |
| NCT00103571Schizophrenia · United States, Puerto Rico | 4 | Completed | Eli Lilly | 600 | |
| NCT00100776Schizophrenia · United States | 4 | Completed | Eli Lilly | 600 | |
| NCT00094549Bipolar Disorder · United States, Lithuania, Puerto Rico and more | 4 | Completed | Eli Lilly | 500 | |
| NCT00091650Borderline Personality Disorder · United States, Belgium, France and more | 3 | Completed | Eli Lilly | 300 | |
| NCT00090012Schizophrenia · United States | 4 | Completed | Eli Lilly | 340 | |
| NCT00088491Schizophrenia · Finland, Turkey | 3 | Completed | Eli Lilly | 1,205 | |
| NCT00088465Schizophrenia · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Dec 2010 | 931 |
| NCT00088049Schizophrenia · United States | 4 | Completed | Eli Lilly | 560 | |
| NCT00088036Borderline Personality Disorder · United States, Argentina, Poland and more | 3 | Completed | Eli Lilly | 450 | |
| NCT00071253Bipolar Disorder · United States | 4 | Terminated | Abbott | 180 | |
| NCT00051298Schizophrenia · United States, Russian Federation | 3 | Completed | Eli Lilly | 107 | |
| NCT00050206Bipolar Disorder · United States | 4 | Completed | Eli Lilly | 130 | |
| NCT00036088Schizophrenia · United States, Argentina, Austria and more | 4 | Completed | Eli Lilly | 530 | |
| NCT00035321Depressive Disorder, Major · United States, Canada | 3 | Completed | Eli Lilly | 600 | |
| NCT00034892Schizophrenia · United States, Canada | 3 | Completed | AstraZeneca | Mar 2005 | |
| NCT00034801Depression · United States | 4 | Completed | Eli Lilly | 378 | |
| NCT00034580Bipolar Disorder · United States | 4 | Completed | Eli Lilly | 326 |
How it is read
Names in the registry
- “Olanzapine”, 33 entries
- “olanzapine”, 17 entries
- “ALKS 3831”, 7 entries
- “Olanzapine Tablets 5 mg”, 2 entries
- “Olanzapine OD Tablets 5 mg”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 41 studies
- Bipolar Disorder, 12 studies
- Depressive Disorder, Treatment-Resistant, 2 studies
- Fasting, 2 studies
- Borderline Personality Disorder, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.